Sarissa Capital Management’s Vor Biopharma VOR Stock Holding History

Sarissa Capital Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468K	Hold	25,399	–	–	0.26%	9
2026 Q1	$453K	Hold	25,399	–	–	0.29%	9
2025 Q4	$332K	Hold	25,399	–	–	0.15%	9
2025 Q3	$1.24M	Sell	25,399 -2	-0%	-$80	0.69%	8
2025 Q2	$823K	Hold	25,401	–	–	0.53%	7
2025 Q1	$365K	Sell	25,401 -5,499	-18%	-$132K	0.24%	7
2024 Q4	$686K	Hold	30,900	–	–	0.21%	8
2024 Q3	$433K	Hold	30,900	–	–	0.11%	9
2024 Q2	$618K	Hold	30,900	–	–	0.1%	9
2024 Q1	$1.46M	Hold	30,900	–	–	0.26%	9
2023 Q4	$1.39M	Hold	30,900	–	–	0.21%	8
2023 Q3	$1.31M	Hold	30,900	–	–	0.18%	9
2023 Q2	$1.91M	Hold	30,900	–	–	0.19%	10
2023 Q1	$3.32M	Hold	30,900	–	–	0.43%	9
2022 Q4	$4.11M	Hold	30,900	–	–	0.49%	9
2022 Q3	$2.46M	Hold	30,900	–	–	0.28%	9
2022 Q2	$3.07M	Sell	30,900 -4,451	-13%	-$456K	0.31%	9
2022 Q1	$4.27M	Hold	35,351	–	–	0.4%	9
2021 Q4	$8.21M	Hold	35,351	–	–	0.71%	9
2021 Q3	$11.1M	Hold	35,351	–	–	0.87%	9
2021 Q2	$13.2M	Hold	35,351	–	–	1.05%	9
2021 Q1	$30.5M	Buy	+35,351	New	+$29.9M	2.92%	9

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Sarissa Capital Management's VOR Position: Q2 2026 in Review

Sarissa Capital Management held its Vor Biopharma (VOR) position steady in Q2 2026 at 25,399 shares worth $468K. The position accounts for 0.26% of the portfolio, ranked #9.

Sarissa Capital Management first reported a position in VOR in Q1 2021 and has held it in 22 quarters since. The position peaked at $30.5M in Q1 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Sarissa Capital Management held 25,399 shares of Vor Biopharma worth $468K as of Q2 2026.
Sarissa Capital Management left its Vor Biopharma share count unchanged in Q2 2026.
Vor Biopharma made up 0.26% of Sarissa Capital Management's portfolio in Q2 2026, its #9 holding.
Sarissa Capital Management first reported a position in Vor Biopharma in Q1 2021 and has held it in 22 quarters since.
Sarissa Capital Management's Vor Biopharma position peaked at $30.5M in Q1 2021.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.